Immunomedics, Inc. (IMMU) Announces New Patent for Antibodies Targeting CD19
12/21/2012 8:50:27 AM
MORRIS PLAINS, N.J., Dec. 21, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that it has received notice that its patent application for "Anti-CD19 antibodies," will issue as US patent No. 8,337,840 on December 25, 2012.
comments powered by